LABT Stock Summary and Trading Ideas (Lakewood-Amedex Biotherapeutics | NASDAQ:LABT)

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

Lakewood-Amedex Biotherapeutics trades on the NASDAQ stock market under the symbol LABT.

As of September 9, 2026, LABT stock price climbed to $2.31 with 1,709,329 million shares trading.

LABT has a beta of -1.93, meaning it tends to be less sensitive to market movements. LABT has a correlation of 0.01 to the broad based SPY ETF.

LABT has a market cap of $5.47 million. This is considered a Sub-Micro Cap stock.

LABT support price is $2.00 and resistance is $2.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LABT shares will trade within this expected range on the day.